General MedicationsINJECTIONStandard
ILUMYA
TILDRAKIZUMAB-ASMN
Standard Dose
100MG/1ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview ILUMYA is listed in Drugs@FDA under application 761067 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient TILDRAKIZUMAB-ASMN Form and strength INJECTABLE;INJECTION - 100MG/1ML Sponsor SUN PHARMA GLOBAL Submission history Latest submission status date: 2025-12-12 00:00:00.
Structured Monograph
Clinical summary
Approval overview ILUMYA is listed in Drugs@FDA under application 761067 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient TILDRAKIZUMAB-ASMN Form and strength INJECTABLE;INJECTION - 100MG/1ML Sponsor SUN PHARMA GLOBAL Submission history Latest submission status date: 2025-12-12 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.